Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][3]. Core Insights - The company achieved a net profit of RMB 3.39 billion in 2025, representing a year-over-year increase of 23.8%, with total revenue reaching RMB 14.8 billion, up 10.1% year-over-year [8]. - The company is actively expanding its overseas market presence, with overseas revenue growing by 20% year-over-year to RMB 3.3 billion, and has registered in 8 new countries [8]. - The gross margin improved to 60.5%, a 0.5 percentage point increase year-over-year, while the net profit margin rose by 2.6 percentage points to 22.9% [8]. - The company forecasts net profits of RMB 4.1 billion, RMB 4.9 billion, and RMB 5.7 billion for 2026, 2027, and 2028 respectively, with year-over-year growth rates of 22%, 20%, and 16% [8][10]. Financial Summary - The company reported a total revenue of RMB 1,482 million for 2025, with a projected increase to RMB 1,758 million in 2026 [12]. - The earnings per share (EPS) for 2025 is projected at RMB 0.30, with expected growth to RMB 0.37 in 2026 [10]. - The price-to-earnings (P/E) ratio is expected to decrease from 17 in 2025 to 14 in 2026, indicating a potentially undervalued stock [10].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 7.3, indicating a potential upside from the current price of HKD 5.86 [2][5]. Core Insights - The company reported a net profit of RMB 3.39 billion for 2025, representing a year-over-year (YOY) increase of 23.8%, which aligns with expectations [6][8]. - The company is actively expanding its overseas market presence, achieving a 20% YOY growth in overseas revenue, totaling RMB 3.3 billion in 2025 [8]. - The gross profit margin improved to 60.5%, a 0.5 percentage point increase YOY, while the net profit margin rose by 2.6 percentage points to 22.9% [8]. Financial Performance - The company achieved total revenue of RMB 14.8 billion in 2025, a YOY increase of 10.1% [8]. - The domestic revenue reached RMB 11.5 billion, growing by 7.5% YOY, driven by increased surgical volumes and higher domestic replacement rates [8]. - The company plans to distribute a dividend of HKD 0.118 per share [8]. Earnings Forecast - The company is expected to achieve net profits of RMB 4.1 billion, RMB 4.9 billion, and RMB 5.7 billion for the years 2026, 2027, and 2028, respectively, with YOY growth rates of 22%, 20%, and 16% [8][10]. - The earnings per share (EPS) are projected to be RMB 0.37, RMB 0.44, and RMB 0.51 for the same years [10]. Valuation Metrics - The price-to-earnings (P/E) ratios for the company are projected to be 14X, 12X, and 10X for 2026, 2027, and 2028, respectively, indicating a low valuation relative to expected earnings growth [8][10].